<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615235</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00051561</org_study_id>
    <secondary_id>U01DK116041</secondary_id>
    <secondary_id>U01DK116040</secondary_id>
    <nct_id>NCT03615235</nct_id>
  </id_info>
  <brief_title>APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)</brief_title>
  <acronym>APOLLO</acronym>
  <official_title>APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation
      and to improve the safety of living kidney donation based upon variation in the
      apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye
      color or blood type. Variation in APOL1 can cause kidney disease. African Americans,
      Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene
      variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of
      kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The National Institutes of Health (NIH)-sponsored collaborative APOL1 Long-term Kidney
      Transplantation Outcomes Network (APOLLO) is charged with prospectively assessing the effects
      of renal-risk variants (RRVs) in the apolipoprotein L1 gene (APOL1) on outcomes for kidneys
      from donors with recent African ancestry and the recipients of their kidneys, after deceased-
      and living-donor renal transplantation. For the purposes of APOLLO, recent African ancestry
      is defined as individuals with similar genetic make-up to those currently residing in Africa.
      APOLLO will also study the impact of APOL1 RRVs on the health of living kidney donors with
      recent African ancestry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to death-censored renal allograft failure from the UNOS database</measure>
    <time_frame>up to 4.5 years</time_frame>
    <description>Time from receipt of kidney transplant to death-censored renal allograft failure. Measured in days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of loss of renal clearance function from clinical laboratory data</measure>
    <time_frame>up to 4.5 years</time_frame>
    <description>Rate of change in the estimated glomerular filtration rate based on the Chronic Kidney Disease - Epidemiology Collaboration Equation (CKD-EPI eGFR). Measured in ml/min/1.73 m2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of change in serum creatinine concentration from clinical laboratory data</measure>
    <time_frame>up to 4.5 years</time_frame>
    <description>Rate of change in the reciprocal of the serum creatinine concentration. Measured as 1/serum creatinine concentration [in mg/dl].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sustained development of overt proteinuria in the outpatient setting.</measure>
    <time_frame>up to 4.5 years</time_frame>
    <description>Overt proteinuria is defined as urine protein:creatinine ratio (UPCR) &gt;500 mg/g, urine albumin:creatinine ratio (UACR) &gt;300 mg/g, or &gt;2+ proteinuria on urine dipstick. This outcome requires repeat documentation of proteinuria using either UPCR, UACR or dipstick test &gt;1 month after initial detection based on clinic data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in kidney function and quantitative proteinuria from baseline pre-donation levels in living kidney donors (to include effects on stages of CKD)</measure>
    <time_frame>up to 4.5 years</time_frame>
    <description>Rate of change (i.e., slope of change) in estimated glomerular filtration rate based on serum creatinine concentration from UNOS and clinic data</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Kidney Failure</condition>
  <condition>Kidney Disease, Chronic</condition>
  <arm_group>
    <arm_group_label>Recipients of a Kidney Transplant</arm_group_label>
    <description>APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Living Kidney Donors</arm_group_label>
    <description>APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood for DNA extraction, serum, urine, kidney biopsy samples.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Thirteen APOLLO Clinical Centers (CCs) will prospectively enroll eligible living kidney
        donors and recipients of kidney transplants from eligible living and deceased kidney donors
        at all transplant programs in the continental United States including Puerto Rico. The
        APOLLO Scientific and Data Research Center (SDRC or Coordinating Center) will support and
        participate in studies determining the impact of donor and recipient APOL1 genotypes on
        kidney transplant outcomes in recipients of a kidney transplant from a donor with recent
        African ancestry, and follow African ancestry living kidney donors for changes in vital
        status, kidney function and proteinuria. In this protocol, recent African ancestry is
        broadly defined as African American, Afro-Caribbean, Hispanic black, and African.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Living Donors:

          -  Living kidney donors with self-reported recent African ancestry (defined as African
             American, Afro-Caribbean, Hispanic black or African) will be eligible for inclusion.

        Exclusion Criteria for Living Donors:

          -  Participants who are unable or unwilling to provide informed consent.

        Inclusion Criteria for Recipients:

          -  Recipients of a kidney transplant from an eligible living or deceased donor with
             recent African ancestry.

          -  Recipients of multi-organ transplants including a kidney plus an additional organ
             (i.e. liver, heart, lung, pancreas, etc.) or pediatric en bloc and dual kidney
             transplants.

        Exclusion Criteria for Recipients:

          -  Participants who are unable or unwilling to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry I. Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M. Reboussin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul L. Kimmel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Natl Institute of Diabetes, Digestive &amp; Kidney Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marva Moxey-Mims, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Natl Health System; George Washington Univ Sch of Med and Health Serv</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie P. Russell, MS</last_name>
    <phone>336-713-4292</phone>
    <email>lrussell@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Smith</last_name>
    <phone>336-713-7531</phone>
    <email>suscsmit@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Basinger, RN</last_name>
      <phone>205-934-0035</phone>
      <email>katherinemiller@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce A. Julian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farshad Palad</last_name>
      <phone>415-476-8695</phone>
      <email>farshad.palad@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gabriel Garcia</last_name>
      <phone>415-476-8695</phone>
      <email>gabriel.garcia@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chi-yuan Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meyeon Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami / Miami Transplant Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissett Tueros</last_name>
      <phone>305-355-5315</phone>
      <email>ltueros@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Alessia Fornoni, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariella Ortigosa-Goggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giselle Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ferry</last_name>
      <phone>404-712-1816</phone>
      <email>elizabeth.ferry@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Stephen O. Pastan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth A. Newell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Bartosic</last_name>
      <phone>410-328-0303</phone>
      <email>abartosic@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan S. Bromberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew R. Weir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darin Ostrander, PhD</last_name>
      <phone>410-614-6702</phone>
      <email>dostran1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel C. Brennan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center / Harvard University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Slack</last_name>
      <phone>617-309-4130</phone>
      <email>Alison.Slack@joslin.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Sylvia E. Rosas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medicine</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Czerr</last_name>
      <phone>216-444-3256</phone>
      <email>czerrj@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Mona D. Doshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Center for Transplantation</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lindsay, MSN, APRN</last_name>
      <phone>314-577-8460</phone>
      <email>kathryn.lindsay@health.slu.edu</email>
    </contact>
    <investigator>
      <last_name>Krista L. Lentine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ichan School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Haydel</last_name>
      <phone>212-241-0255</phone>
      <email>brandy.haydel@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miah Li</last_name>
      <phone>212-305-8392</phone>
      <email>mtl2156@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Sumit Mohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Edusei, BA</last_name>
      <phone>212-746-6112</phone>
      <email>eme2005@med.cornelle.edu</email>
    </contact>
    <investigator>
      <last_name>Darshana M. Dadhania, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynnette Moats</last_name>
      <phone>919-681-3399</phone>
      <email>lynnette.moats@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Rasheed A. Gbadegesin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitzie Spainhour, LPN</last_name>
      <phone>336-716-4246</phone>
      <email>mhspain@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Smith, BS</last_name>
      <phone>336-713-7531</phone>
      <email>suscsmit@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Barry I. Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amber M. Reeves-Daniel, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Czerr</last_name>
      <phone>216-444-3256</phone>
      <email>czerrj@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Emilio D. Poggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miah Li</last_name>
      <phone>212-305-8392</phone>
      <email>mtl2156@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Deirdre L. Sawinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitta Brannon</last_name>
      <phone>615-343-1218</phone>
      <email>brigitta.brannon@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Kelly A. Birdwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Ptak</last_name>
      <phone>608-262-0731</phone>
      <email>ldptak@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Astor, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Freedman BI, Moxey-Mims M. The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO. Clin J Am Soc Nephrol. 2018 Jun 7;13(6):940-942. doi: 10.2215/CJN.01510218. Epub 2018 Apr 27.</citation>
    <PMID>29703792</PMID>
  </reference>
  <reference>
    <citation>Freedman BI, Julian BA. Evaluation of Potential Living Kidney Donors in the APOL1 Era. J Am Soc Nephrol. 2018 Apr;29(4):1079-1081. doi: 10.1681/ASN.2018020137. Epub 2018 Mar 9.</citation>
    <PMID>29523593</PMID>
  </reference>
  <reference>
    <citation>Freedman BI, Locke JE, Reeves-Daniel AM, Julian BA. Apolipoprotein L1 Gene Effects on Kidney Transplantation. Semin Nephrol. 2017 Nov;37(6):530-537. doi: 10.1016/j.semnephrol.2017.07.006. Review.</citation>
    <PMID>29110760</PMID>
  </reference>
  <reference>
    <citation>Julian BA, Gaston RS, Brown WM, Reeves-Daniel AM, Israni AK, Schladt DP, Pastan SO, Mohan S, Freedman BI, Divers J. Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index. Am J Transplant. 2017 Jun;17(6):1540-1548. doi: 10.1111/ajt.14113. Epub 2017 Jan 3.</citation>
    <PMID>27862962</PMID>
  </reference>
  <reference>
    <citation>Dorr CR, Freedman BI, Hicks PJ, Brown WM, Russell GB, Julian BA, Pastan SO, Gautreaux MD, Muthusamy A, Chinnakotla S, Hauptfeld V, Bray RA, Kirk AD, Divers J, Israni AK. Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes. PLoS One. 2016 Apr 7;11(4):e0152775. doi: 10.1371/journal.pone.0152775. eCollection 2016.</citation>
    <PMID>27054572</PMID>
  </reference>
  <reference>
    <citation>Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J. APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors. Transplantation. 2016 Jan;100(1):194-202. doi: 10.1097/TP.0000000000000969.</citation>
    <PMID>26566060</PMID>
  </reference>
  <reference>
    <citation>Freedman BI, Julian BA. Should kidney donors be genotyped for APOL1 risk alleles? Kidney Int. 2015 Apr;87(4):671-3. doi: 10.1038/ki.2015.16.</citation>
    <PMID>25826538</PMID>
  </reference>
  <reference>
    <citation>Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Hicks PJ, Palmer ND, Adams PL, Palanisamy A, Reeves-Daniel AM, Divers J. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant. 2015 Jun;15(6):1615-22. doi: 10.1111/ajt.13223. Epub 2015 Mar 24.</citation>
    <PMID>25809272</PMID>
  </reference>
  <reference>
    <citation>Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011 May;11(5):1025-30. doi: 10.1111/j.1600-6143.2011.03513.x. Epub 2011 Apr 12.</citation>
    <PMID>21486385</PMID>
  </reference>
  <reference>
    <citation>Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, Dyer C, Conte S, Genovese G, Ross MD, Friedman DJ, Gaston R, Milford E, Pollak MR, Chandraker A. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant. 2012 Jul;12(7):1924-8. doi: 10.1111/j.1600-6143.2012.04033.x. Epub 2012 Apr 4.</citation>
    <PMID>22487534</PMID>
  </reference>
  <reference>
    <citation>Doshi MD, Ortigosa-Goggins M, Garg AX, Li L, Poggio ED, Winkler CA, Kopp JB. APOL1 Genotype and Renal Function of Black Living Donors. J Am Soc Nephrol. 2018 Apr;29(4):1309-1316. doi: 10.1681/ASN.2017060658. Epub 2018 Jan 16.</citation>
    <PMID>29339549</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apolopoprotein L1 gene (APOL1)</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Kidney Donor</keyword>
  <keyword>United Network for Organ Sharing (UNOS)</keyword>
  <keyword>Association of Organ Procurement Organizations (AOPO)</keyword>
  <keyword>Kidney Transplantation Outcomes Network</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study participants will have the option of receiving their APOL1 genotype test result from a CLIA research lab. Deceased donor family decision makers will also have the option of receiving their loved one's APOL1 genotype test result from a CLIA research lab. Results will be made available after enrollment is complete, likely in year 3 of the study. Those who wish to receive these results will have been informed of benefits and risks of requesting and receiving this information prior to consenting to participate in APOLLO and again at the time of requesting test results. Infographics to aid in the decision process for requesting IPD are provided at the time of consent and on the APOLLO website. Prior to sending IPD, participants and deceased donor family decision makers will be asked to verify that they received and understand the information. They will be able to ask questions to local study staff or the APOLLO SDRC (Coordinating Center).</ipd_description>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Approximately 3 years after enrollment begins (once all testing is performed at once). Results will be available for 12 months.</ipd_time_frame>
    <ipd_access_criteria>Requests for return of IPD will be made via the APOLLO website. Individual letters containing IPD and explanations of results will come via the USPS.</ipd_access_criteria>
    <ipd_url>http://TheApolloNetwork.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

